Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.